RET Fusions in NSCLC: Current Management

Episode
146
Soundcloud
Share

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about  NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pipeline.
 
Dr. Justin Gainor, the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major research interests have focused on targeted therapy and immunotherapy.
 
Dr. Lizza Hendricks, Assistant Professor at research institute GROW, School for Oncology and Developmental Biology of Maastricht University in the Netherlands. Her focus area is thoracic oncology, in particular, prevention and optimal treatment of brain metastases in lung cancer and targeted therapy. Since 2019, Dr. Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht.

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Lizza Hendriks
Lizza Hendriks

MD, PhD

Assistant Professor
Research Institute GROW, School for Oncology and Developmental Biology of Maastricht University
Justin Gainor
Justin F. Gainor

MD

Director of the Center for Thoracic Cancers
Massachusetts General Hospital (MGH)